Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: eliezerm_vanallen@dfci.harvard.edu.

Editorial

Chris Labaki et al. Eur Urol Oncol. 2022 Dec.

. 2022 Dec;5(6):719-721.

doi: 10.1016/j.euo.2022.01.004. Epub 2022 Jan 31.

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: eliezerm_vanallen@dfci.harvard.edu.

No abstract available

Comment on

TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. Chou J, et al. Eur Urol Oncol. 2022 Dec;5(6):714-718. doi: 10.1016/j.euo.2021.11.005. Epub 2022 Feb 23. Eur Urol Oncol. 2022. PMID: 35216942 Free PMC article.